Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial With "Off-The-Shelf" Third-Party BPX-501 Donor Lymphocyte Immunotherapy to Treat Persistence or Relapse of Hematologic Malignancies After Allogeneic Stem Cell Transplantation

NCT03807063 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT03807063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03807063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial With "Off-The-Shelf" Third-Party BPX-501 Donor Lymphocyte Immunotherapy to Treat Persistence or Relapse of Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1
Overall status
Withdrawn
Start date
January 2, 2020
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute bilineal leukemia, myelodysplastic/myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm, unclassifiable, myeloproliferative neoplasm, recurrent acute biphenotypic leukemia, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia, recurrent blastic plasmacytoid dendritic cell neoplasm, recurrent chronic lymphocytic leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent chronic myelomonocytic leukemia, recurrent myelodysplastic syndrome